Advertisement

Topics

GSK Hands Nerve Drug Back to Ionis as RNA Battle Heats Up

08:33 EDT 11 Aug 2017 | Xconomy

A race is on to bring two new RNA-based drugs for a rare, debilitating nerve disease called familial amyloid polyneuropathy (FAP). And GlaxoSmithKline has just dropped out of it. This morning, Ionis Pharmaceuticals (NASDAQ: IONS) said that it has regained full rights, from GSK, to a drug called inotersen, which the Carlsbad, CA, company expects […]

Original Article: GSK Hands Nerve Drug Back to Ionis as RNA Battle Heats Up

NEXT ARTICLE

More From BioPortfolio on "GSK Hands Nerve Drug Back to Ionis as RNA Battle Heats Up"

Quick Search
Advertisement
 

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...